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Abstract 1 
Purpose: When patients are mechanically ventilated for more than 5 days, they are usually 2 
declined as donors for lung transplantation (LTx); thus, the long-term outcomes of LTx from such 3 
donors remain unclear. We investigated the feasibility of LTx from donors that had been 4 
mechanically ventilated for prolonged periods. 5 
Methods: The subjects of this retrospective comparative investigation were 31 recipients of LTx 6 
from donors who had been mechanically ventilated for <5 days (short-term group) and 50 7 
recipients of LTx from donors who had been mechanically ventilated for ≥5 days (long-term 8 
group).  9 
Results: The median duration of donor mechanical ventilation was 3 days in the short-term group 10 
and 8.5 days in the long-term group. However, other than the difference in the duration of donor 11 
ventilation, there were no significant differences in the clinical characteristics of the donors or 12 
recipients between the groups. The overall survival rate after LTx was comparable between the 13 
long-term group and short-term group (5-year survival rate, 66.6% vs. 75.2%). 14 
Conclusion: The potential inclusion of donors who have been on mechanical ventilation for more 15 
than 5 days could be a feasible strategy to alleviate donor organ shortage. 16 
 17 
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Introduction 1 
Extended-criteria donor (ECD) lungs from brain-dead donors have been used widely for lung 2 
transplantation (LTx) to help resolve the problem of donor shortage [1]. Among ECDs, those 3 
supported by mechanical ventilation for prolonged periods are generally considered as marginal, 4 
because prolonged mechanical ventilation in brain-dead donors can impair the lungs by causing 5 
neurogenic lung edema, atelectasis, and/or ventilator-associated pneumonia [2, 3]. In fact, 6 
mechanical ventilation for more than 48 hours was found to be correlated with pneumonia in 7 
donor lungs [4]. Accordingly, subjects mechanically ventilated for more than 5 days are usually 8 
declined as donors for LTx; however, no definitive data on the long-term outcomes of LTx from 9 
such donors have been published to validate this generally accepted practice [2, 3]. Although we 10 
recently reported a negative impact of prolonged mechanical ventilation on the early outcomes 11 
after LTx [5], such as primary graft dysfunction (PGD), we still consider that the inclusion of 12 
subjects mechanically ventilated for prolonged periods as LTx donors could be an effective 13 
strategy to expand the donor pool for LTx. This retrospective study compares the outcomes of 14 
LTx from donors mechanically ventilated for short periods (<5 days) with those from donors 15 
mechanically ventilated for prolonged periods (≥5 days), and investigates the feasibility of LTx 16 
from donors mechanically ventilated for prolonged periods. 17 
 18 
Methods 19 
Patients 20 
We reviewed, retrospectively, the outcomes of LTx from brain-dead donors, for various end-stage 21 
lung diseases at Okayama University Hospital. Between January, 2001 and May, 2017, we 22 
performed 81 LTxs from brain-dead donors. LTxs from donors who had been on mechanical 23 
ventilation for <5 days were designated as the short-term (ST) group (n = 31), and LTxs from 24 
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donors who had been on mechanical ventilation for ≥5 days were designated as the long-term 1 
(LT) group (n = 50). We assessed the donor and recipient characteristics, as well as the 2 
postoperative outcomes. The donor lungs were assigned lung donor scores based on the following 3 
five variables proposed by Oto et al.: age, smoking history, chest X-ray findings, 4 
presence/absence of secretions, and the ratio of the arterial oxygen tension to the inspired oxygen 5 
fraction (PaO2/FiO2) [6]. According to this scoring system, the former four variables are assigned 6 
scores of 0 and 3, and the PaO2/FiO2 is assigned a weighted score of 0 and 6, with the lung donor 7 
scores ranging from 0 (ideal donor lungs) to 18 (worst possible donor lungs). The lung allocation 8 
score (LAS) of each recipient, indicative of the preoperative severity of the underlying lung 9 
diseases, was calculated retrospectively using the LAS calculator published on the OPTN website 10 
(https://optn.transplant.hrsa.gov/resources/allocation-calculators/las-calculator/) in November 11 
2016. Chronic lung allograft dysfunction (CLAD)-free survival was defined as the time between 12 
the LTx and the date of disease onset. Overall survival was defined as the time between LTx and 13 
death. The study protocol (No. 1710-018) was approved by the institutional review board of 14 
Okayama University Hospital.  15 
 16 
Donor and recipient selection and the transplantation procedures 17 
Patients who require LTx are registered with the Japan Organ Transplantation Network. Because 18 
the LAS system has not yet been adopted in Japan, the allocation of organs from brain-dead 19 
donors is still based mainly on the waiting time. The transplant procedures have been described 20 
previously [7]. The graft ischemic time was defined as the ischemic time for the second 21 
transplanted lung in cases of bilateral LTx. 22 
  23 
Postoperative care 24 
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The postoperative management of the LTx recipients, including the immunosuppressive therapy 1 
and prophylactic therapies against viral and fungal infections, has been described elsewhere [7, 2 
8]. Patients were assigned PGD grades according to the definition of PGD proposed by the 3 
International Society for Heart and Lung Transplantation (ISHLT) [9]. All the LTx recipients 4 
received triple-immunosuppression therapy, consisting of tacrolimus or cyclosporine, 5 
mycophenolate mofetil (MMF), or azathioprine, and a corticosteroid. Basiliximab was given on 6 
postoperative days (PODs) 1 and 4 to patients identified as being at risk of the development of 7 
renal dysfunction. Acute rejection was treated by bolus intravenous corticosteroid administration 8 
for 3 days. CLAD was diagnosed based on the classification system proposed by the ISHLT [10]. 9 
 10 
Statistical analysis 11 
All statistical analyses were performed using the GraphPad Prism5 software (San Diego, CA, 12 
USA). Normally distributed continuous variables were expressed as means ± standard deviations. 13 
Bivariate comparison of continuous variables was performed by Student’s t test. Associations 14 
between categorical variables were tested by Fisher's exact test. The postoperative survival rate 15 
was analyzed by the Kaplan–Meier method, with the log-rank test used to determine the 16 
significance of differences between the groups. Differences were considered significant at p 17 
<0.05. The results were analyzed as of July 31, 2017. 18 
 19 
Results 20 
Donor characteristics 21 
Table 1 summarizes the donor characteristics. The duration of mechanical ventilation of the 22 
donors from both groups ranged from 1 to 326 days, with the median duration being 3 days in the 23 
ST group and 8.5 days in the LT group (Fig. 1). Despite the difference in the duration of 24 
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ventilation, the lung donor scores were similar in the two groups, except that among the five 1 
variables forming the basis for the lung donor score, the score for secretions was significantly 2 
higher in the LT group than in the ST group (p = 0.021). Table 2 shows the distribution of scores 3 
for the variables comprising the lung donor score. There were no significant differences in the 4 
distribution of items outside the standard acceptability criteria, such as PaO2/FiO2 <300 mmHg, 5 
age over 55 years, or history of smoking >20 pack-years, between the two groups.  6 
 7 
Recipient characteristics 8 
As shown in Table 3, the preoperative characteristics of the recipients were similar between the 9 
LT group and the ST group. Of note, the mean waiting time for LTx in both groups was about 2 10 
years. Table 4 summarizes the postoperative outcomes of the recipients, with no remarkable 11 
differences observed between the groups. Any length of mechanical ventilation led to CLAD 12 
(Fig. 2). The CLAD-free survival rate in the LT group was nearly the same as that in the ST 13 
group (5-year survival rate, 57.0% vs. 57.5%) (Fig. 3). The overall survival rate in the LT group 14 
was also comparable to that in the ST group (5-year survival rate, 66.6% vs. 75.2%) (Fig. 4). 15 
 16 
Discussion 17 
In this study, the outcomes of LTx from donors ventilated for prolonged periods (≥5 days) were 18 
equivalent to those of LTx from donors ventilated for a short period (<5 days). This suggests that 19 
the inclusion of donors ventilated for more than 5 days could expand the donor pool for LTx. 20 
Thus, our results indicate that prolonged mechanical ventilation of donors is not a 21 
contraindication per se to donation, and that the utilization of the donor lungs should be based 22 
more on a comprehensive assessment of the donor lung condition; for example, by evaluating the 23 
donor lung score. 24 
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Despite the prolonged ventilation of donors in our LT group, these donors showed adequate 1 
lung quality for LTx in terms of the long-term postoperative outcomes. Generally, lung transplant 2 
centers are reluctant to accept brain-dead donors who have been on prolonged ventilation. In 3 
addition to neurogenic pulmonary edema or acute lung injury induced by hemodynamic, 4 
neurogenic, and hormonal changes after brainstem death [11], prolonged ventilation in brain-dead 5 
donors also frequently causes atelectasis and ventilator-associated pneumonia. Accordingly, early 6 
lung retrieval from brain-dead donors is considered important for securing donor lung quality 7 
[12]. Thus, it has been recommended that brain-dead donors mechanically ventilated for more 8 
than 5 days be declined as organ donors for LTx [2, 3, 13]. However, the aggressive donor 9 
management reported recently by some centers [14-17], could help to maintain the condition of 10 
donor lungs even after prolonged ventilation. In fact, in this study, the lung quality, as evaluated 11 
by the lung donor score, was maintained even in donors who had been on mechanical ventilation 12 
for prolonged periods under aggressive donor management, which is practiced nationwide in 13 
Japan [16, 17]. To maintain the integrity of the limited number of donor lungs in Japan, special 14 
transplant management doctors have been sent to donor hospitals to assess the lung function and 15 
support the provision of intensive care for the donors. Through this system, ECD lungs ventilated 16 
for prolonged periods have been used aggressively to maximize the limited organ transplant 17 
opportunities in Japan. The fact that the rate of chest CT was more than 70.0% in both groups 18 
also indicates that precise assessment using chest CT is appropriate to evaluate the lungs of 19 
potential donors ventilated for prolonged periods. Moreover, while lung donors mechanically 20 
ventilated for a short period could be developing pneumonia at the time of organ procurement, 21 
lung donors mechanically ventilated for a prolonged period would have already developed 22 
pneumonia prior to procurement, which could be treated with adequate antibiotic use or be 23 
declined for donation if the treatment proves ineffective. 24 
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The recipient characteristics were similar in the two groups. The waiting time for cadaveric 1 
LTx was about 2 years in this study, consistent with the national average in Japan, because of the 2 
extreme donor organ shortage. In this situation, living-donor lobar LTx is still a realistic option 3 
for urgent LTx in Japan; therefore, recipients with high LAS tend to receive living-donor lobar 4 
LTx at our hospital [7]. On the other hand, cardiopulmonary bypass was used for most of the 5 
bilateral LTxs, to prevent uncontrolled reperfusion of the first implanted lung and to utilize its 6 
advantage of providing intraoperative hemodynamic stability. This is because the donor lungs in 7 
this study were marginal for LTx, with an average lung donor score of close to 7, which is the 8 
upper limit for lung utilization, as reported previously [6]. 9 
Prolonged mechanical ventilation of the lung donors had no negative impact on the 10 
postoperative outcomes of the LTx recipients in this study. We previously reported the negative 11 
impact of prolonged mechanical ventilation in the development of PGD after LTx, including 12 
cadaveric LTx and living-donor lobar LTx; however, we did not find a significant difference in 13 
the PGD grade distribution in the exclusively cadaveric LTx in this study [5]. Despite the 14 
significantly larger amount of secretions in the donors of the LT group, there was no difference in 15 
the incidence of pneumonia in the recipients between the two groups, although donor-to-host 16 
transmission of infection has been shown to occur frequently after LTx [4]. Moreover, prolonged 17 
positive-pressure mechanical ventilation may potentially cause emphysematous changes in the 18 
donor lungs, resulting in the early development of CLAD in recipients; however, there was no 19 
significant difference in the incidence of CLAD between the groups in this study. Thus, the 20 
overall use of lungs from donors on mechanical ventilation for prolonged periods had no 21 
significant effect on the overall survival rate. Our results provide encouragement for the use of 22 
ECD lungs for LTx, even after prolonged mechanical ventilation, if the lung quality is favorable 23 
for LTx. 24 
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     Compared with other countries, the number of brain-dead organ donations in Japan is still 1 
low, despite the modification of the Organ Transplant Law in 2010. The organ donation system 2 
and the social background contributed to the prolonged ventilation of the donors in this study. In 3 
Japan, unlike in many other countries, there is no legislation related to potential donor referral, 4 
and the option to retrieve organs from brain-dead patients is a decision made by the physicians in 5 
charge [18]. Consequently, it takes a longer for informed consent for organ donation to be 6 
obtained after identification of a potential donor, leading to prolonged ventilation of the donor 7 
lung. Furthermore, the pre-retrieval time tends to be longer for pediatric donors than for adult 8 
donors. Since there have been only 12 cases of donation from subjects <15 years of age between 9 
the first donation from a brain-dead donor in February, 1999 and 2016 in Japan, it generally takes 10 
a long time to confirm the family’s consent for pediatric donors. In fact, all four pediatric donors 11 
were included in the LT group in this study.  12 
     Our study had several limitations. First, it was a retrospective observational study 13 
conducted at a single transplant center. Second, the number of recipients enrolled was small 14 
because the number of donations from brain-dead donors is still limited in Japan. Third, the 15 
follow-up period was still intermediate in some cases, and longer-term follow-up is required for 16 
more reliable evaluation.  17 
     In conclusion, LTx from donors on mechanical ventilation for prolonged periods (≥5 days) 18 
yielded favorable outcomes, comparable to those of LTx from donors on mechanical ventilation 19 
for short periods (<5 days). Our results suggest that the utilization, under aggressive donor 20 
management, of selected donors on mechanical ventilation for prolonged periods, considered as 21 
marginal donors, could be a feasible strategy to expand the donor pool for LTx, and should not 22 
always be precluded if careful selection and evaluation is conducted. 23 
 24 
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Figure Legends 1 
Fig. 1. Distribution of the duration of mechanical ventilation in the brain-dead donors. The 2 
duration of ventilation ranged from 1 to 326 days in 81 donors (<5 days in 31 cases and ≥5 days 3 
in 50 cases). 4 
 5 
Fig. 2. Distribution of the duration of mechanical ventilation in the brain-dead donors and 6 
patients with chronic lung allograft dysfunction. The red bar indicates a case of developing 7 
chronic lung allograft dysfunction. 8 
 9 
Fig. 3. Chronic lung allograft dysfunction (CLAD)-free survival after lung transplantation. The 5-10 
year CLAD-free survival rate in the long-term (LT) group was similar to that in the short-term 11 
(ST) group (57.0% vs. 57.5%). There was no significant difference in the CLAD-free survival 12 
rate between the groups (p = 0.64).  13 
 14 
Fig. 4. Overall survival after lung transplantation. The 5-year survival rate in the long-term (LT) 15 
group was comparable to that in the short-term (ST) group (66.6% vs. 75.2%), and there was no 16 
significant difference in the overall survival rate between the groups (p = 0.85). 17 
 18 
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Table 1. Donor characteristics
Variables
Short-term group
(n=31)
Long-term group
(n=50)
P-value
Age (years) 47.2±14.1 42.3±15.8 0.16
<18 years 0 4 (8%) 0.29
Gender
Male 16 (51.6%) 31 (62.0%) 0.37
Female 15 (48.4%) 19 (38.0%)
Body mass index (kg/m2) 23.0±5.4 23.2±5.5 0.87
Smoking history
Yes 16 (51.6%) 27 (54.0%) 1.00
No 15 (48.4%) 23 (46.0%)
Cause of death
Intracranical bleeding 19 (61.3%) 28 (56.0%) 0.82
Hypoxic brain injury 4 (12.9%) 11 (22.0%) 0.39
Traumatic brain injury 6 (19.4%) 8 (16.0%) 0.77
Cerebro-vascular accident 2 (6.5%) 2 (4.0%) 0.63
Other 0 1 (2.0%) 1.00
 3 (range, 1-4) 8.5 (range, 5-326)
Yes 23 (74.2%) 36 (72.0%) 1.00
No 8 (25.8%) 14 (28.0%)
PaO2/FiO2 414.1±99.6 434.0±117.6 0.44
Lung donor score 6.2±2.9 5.7±3.1 0.52
Age score 1.2±1.2 0.8±1.1 0.16
Smoking history score 0.4±0.6 0.3±0.6 0.41
Chest X- ray score 1.4±0.9 1.3±1.0 0.95
Secretions score 1.0±0.5 1.3±0.5 0.021
PaO2/FiO2 score 2.2±2.2 2.0±2.3 0.66
Ex-vivo lung perfusion use 0 1 (2.0%) 1.00
Median duration of mechanical
ventilation (days)
Chest computed tomographic
assessment
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Table 2. Distribution of the lung donor score
Category Stratification Score
Short-term group
(n=31)
Long-term group
(n=50)
P-value
Age (years) <45 0 13 (41.9%) 27 (54.0%) 0.36
45-54 1 6 (19.4%) 13 (26.0%) 0.59
55-59 2 6 (19.4%) 3 (6.0%) 0.079
≥60 3 6 (19.4%) 7 (14.0%) 0.55
<20 0 20 (64.5%) 39 (78.0%) 0.21
20-39 1 9 (29.0%) 8 (16.0%) 0.17
40-59 2 2 (6.5%) 2 (4.0%) 0.63
≥60 3 0 1 (2.0%) 1.00
Chest X-ray Clear 0 7 (22.6%) 13 (26.0%) 0.80
Minor 1 8 (25.8%) 15 (30.0%) 0.80
Opacity ≤1 lobe 2 14(45.2%) 14 (28.0%) 0.15
Opacity >1 lobe 3 2 (6.5%) 8 (16.0%) 0.30
Secretions None 0 3 (9.7%) 1 (2.0%) 0.15
Minor 1 24 (77.4%) 33 (66.0%) 0.32
Moderate 2 4 (12.9%) 16 (32.0%) 0.066
Major 3 0 0 -
PaO2/FiO2 >450 0 12 (38.7%) 28 (56.0%) 0.17
351-450 2 9 (29.0%) 9 (18.0%) 0.28
301-350 4 5 (16.1%) 3 (6.0%) 0.25
≤300 6 5 (16.1%) 10 (10.0%) 0.77
Smoking history
(pack-years)
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Table 3. Recipient characteristics
Variables
Short-term group
(n=31)
Long-term group
(n=50)
P-value
Age at lung transplantation (years) 40.3±13.7 37.5±15.1 0.42
Gender
Male 13 (41.9%) 25 (50.0%) 0.50
Female 18 (58.1%) 25 (50.0%)
Diagnosis
Interstitial pneumonia 11 (35.5%) 14 (28.0%) 0.62
Pulmonary hypertension 5 (16.1%) 9 (18.0%) 1.00
Pulmonary graft-versus host disease 3 (9.7%) 8 (16.0%) 0.52
Bronchiectasis 1 (3.2%) 6 (12.0%) 0.24
Emphysema 2 (6.5%) 5 (10.0%) 0.70
Lymphangioleiomyomatosis 4 (12.9%) 4 (8.0%) 0.47
Diffuse panbronchiolitis 2 (6.5%) 2 (4.0%) 0.63
Chronic lung allograft dysfunction 1 (3.2%) 2 (4.0%) 1.00
Other diseases 2 (6.5%) 0 0.14
Body mass index (kg/m2) 18.6±4.8 19.2±3.9 0.60
Lung allocation score 38.6±5.5 38.4±6.7 0.59
Waiting time (days) 721.1±497.3 835.6±747.3 0.46
Preoperative condition
Tracheostomy 1 (3.2%) 4 (8.0%) 0.64
Ventilator 1 (3.2%) 3 (6.0%) 1.00
Lung transplant procedure
Bilateral 22 (71.0%) 38 (76.0%) 0.61
Single 9 (29.0%) 12 (24.0%)
Cardiopulmonary bypass use 24 (77.4%) 36 (72.0%) 0.79
Total ischemic time (min) 479.1±118.7 515.1±131.0 0.22
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Table 4. Postoperative results
Variables
Short-term group
(n=31)
Long-term group
(n=50)
P-value
24 (38.7%) 40 (40.0%) 1.00
Extracorporeal membrane oxygenation 3 (9.7%) 2 (4.0%) 0.37
Tracheostomy 12 (38.7%) 15 (30.0%) 0.47
Ventilator support (days) 12.9±15.5 18.0±35.5 0.46
Basiliximab usage 11 (35.5%) 18 (36.0%) 1.00
Acute rejection episodes 0.55±0.80 0.36±0.66 0.26
Antibody mediated rejection 3 (9.7%) 2 (4.0%) 0.37
Postoperative pneumonia within 30 days 9 (29.0%) 21 (42.0%) 0.34
Bronchial complication per anastomosis 3/53 (5.7%) 10/88 (11.4%) 0.37
30-day mortality 1 (3.2%) 1 (2.0%) 1.00
FEV1, 2 years after LTx (L) 1.83±0.79 1.87±0.65 0.85
FVC,  2 years after LTx (L) 2.26±0.91 2.20±0.72 0.79
TLC,  2 years after LTx (L) 3.98±1.37 3.82±0.88 0.63
398.3±102.8 419.2±119.2 0.52
9 (29.0%) 17 (34.0%) 0.81
Primary graft dysfunction of grade 2 or 3 by 48
and 72 hours after LTx
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; LTx, lung transplantation; TLC,
total lung capacity
Lung infection between discharge and 2 years
after LTx
6-minute walk distance,  2 years after LTx (m)
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